Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism.
(PMID: 24057162) Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.
(PMID: 23808982) A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (PMID: 23808982) Nowadays, the new anticoagulants, such as dabigatran, rivaroxaban and apixaban, show potential advantages over classical treatments.
(PMID: 23117646) In a recently completed phase III trial, apixaban also demonstrated promising efficacy and safety in that indication.
(PMID: 22795419).
